Veru Inc. (VERU) Stock

Veru Inc. (VERU) is a Healthcare stock trading at $2.64 (as of 2026-08-21), with a market capitalization of $42.37M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Veru Inc. is an oncology biopharmaceutical company developing medicines for cancer management. Its commercial products include FC2 female/internal condom for dual protection against unintended pregnancy and STIs, and its pipeline includes investigational therapies such as enobosarm and sabizabulin, alone and in combination, being studied for metastatic breast cancer.

Understand Veru Inc.: how it makes money

Veru develops oncology biopharmaceutical medicines and commercializes FC2 female/internal condoms, generating revenue from selling FC2 through U.S. prescription channels and public sector/public health buyers, while its profit outlook depends on progress toward medicines such as Enobosarm in late stage clinical development.

The company is currently an operating loss business, with small commercial revenue and a pipeline still in clinical development, so overall profitability depends on whether late stage and future clinical outcomes translate into meaningful, repeatable product revenue.

Revenue by segment (latest quarter)
FC2 US Rx	$0.0B
Global Public Sector	$0.0B

Business quality (Weak): Current results show negative operating economics relative to revenue, while multiple operating KPIs focus on both FC2 prescription uptake and clinical program execution, meaning execution risk is central to the story.

Bull case

Commercial product with established distribution channels: FC2 female/internal condoms are sold to ministries of health, government health agencies, U.N. agencies, nonprofit organizations, and commercial partners, including a U.S. prescription business.
Late stage pipeline program: Enobosarm is an oral selective androgen receptor agonist in phase III clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer, which is a potential path to future revenue if successful.

Bear case

Negative operating profitability: Operating margin is deeply negative for the latest reported period (2024-06-30), indicating that operating expenses far exceed revenue at this time.
Clinical and execution uncertainty: Several operating KPIs relate to phase 2b and dropout rate, reflecting that patient-level outcomes and retention during trials can materially affect development progress.
FC2 business concentration and transition risk: Operational metrics include headcount after FC2 business sale, which suggests ongoing restructuring or changes tied to the FC2 business.

Valuation — source: SEC EDGAR (first-party)
Price	$2.64
Market Cap	$42.37M
Price / Book	1.22
Price / Sales	5.24
FCF Yield	-153.1%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$16.89M
Net Margin	-223.9%
Revenue Growth (YoY)	-100.0%
EPS Growth (YoY)	614.3%
FCF Growth (YoY)	41.0%

Valuation vs Sector & Industry
Sector P/E (Healthcare)	21.7
Industry P/E (Pharmaceutical Products)	17.0

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	Alyeska Investment Group, L.P. ($2.21M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Mitchell S. Steiner
Employees	210
Country	US
IPO Date	1999-02-11

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.